When German Gallo, a 42-year-old businessman in Lima, Peru, started having episodes of double vision and a feeling of pressure in his skull last year, he quickly went to his local doctor. A series of brain scans found three large sausage-shaped aneurysms in his right carotid artery where it enters the brain. After unsuccessful treatments in several countries, Gallo came to the University of Miami Health System.
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, collaborating with outside investigators, has discovered a new pathway of inflammation-driven cancer development. Their findings, “Initiation of Inflammatory Tumorigenesis by CTLA4 Insufficiency Due to Type 2 Cytokines,” were published online on January 26 by the Journal of Experimental Medicine.
Scientists in the international Illuminating the Druggable Genome (IDG) project, including the University of Miami Miller School of Medicine, are taking an unprecedented approach to discovering new medical therapies. They’re exploring the 38 percent of the human genome that is considered “dark” or largely untapped – so far -- for potential new drug targets.
Although it has been nearly 50 years since Stuart R. Weiss, M.D. ’71, graduated from the University of Miami School of Medicine, he is still dedicated to ensuring the future of his medical alma mater. Weiss, an endocrinologist, has been a generous supporter of the medical school for more than 40 years. His first gift to the school came just three years after graduation.
In hopes of finding new ways to potentially prevent the debilitating effects of arthritis in different regions of the ankle, Amiethab A. Aiyer, M.D., chief of the Foot & Ankle Service and assistant professor in the University of Miami Miller School of Medicine’s Division of Orthopaedic Surgery, recently received a prestigious research grant from the American Orthopaedic Foot & Ankle Society (AOFAS).
Barbara A. Vance, Ph.D., CRA, will join Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine on March 17 as assistant vice president and associate director for administration. Vance will be a senior member of Sylvester’s leadership team, responsible for efficient operations and financial performance, including submission of the National Cancer Institute (NCI) Cancer Center Support Grant.
Dr. Jaime Merchan is thrilled that Sylvester Comprehensive Cancer Center has reached the milestone number of 100 patients enrolled in a single year in its Phase 1 clinical trials program. The program, which tests new drugs and other novel treatment strategies for advanced solid tumors and hematological malignances, offers these patients something they couldn’t find elsewhere: hope.
Patients treated with chemotherapy for some of the most common types of cancer at Dedicated Cancer Centers have higher survival rates compared to patients treated at other types of hospitals, according to new analysis conducted by Milliman for the Alliance of Dedicated Cancer Centers. Sylvester Comprehensive Cancer Center is one of only 11 members of the Alliance of Dedicated Cancer Centers.
Sylvester Comprehensive Cancer Center has once again been recognized as a Cancer Center of Excellence by the State of Florida — one of just four cancer centers in the state, and the only one in South Florida, to have earned this honor. The designation recognizes providers that exceed service standards and excel in providing quality, comprehensive and patient-centered, coordinated care for cancer patients in Florida.
The UHealth Process Improvement Team is launching its first Process Improvement Showcase and welcomes individuals and teams from across the University of Miami Health System to participate. All students, faculty and staff are encouraged to get involved. The showcase allows for teams to display and share their process improvement success stories with colleagues from all areas of the health system.